These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33515803)

  • 1. Effects of chronic HBV infection on lipid metabolism in non-alcoholic fatty liver disease: A lipidomic analysis.
    Li H; Xu QY; Xie Y; Luo JJ; Cao HX; Pan Q
    Ann Hepatol; 2021; 24():100316. PubMed ID: 33515803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical study of non-alcoholic fatty liver disease and its combined the chronic HBV infection].
    He J; Zeng YL; Li W; Guo EE; Li JL; Kang Y; Shang J
    Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):618-622. PubMed ID: 29056013
    [No Abstract]   [Full Text] [Related]  

  • 3. [Study of reactive oxygen species and adiponectin for chronic HBV infection combined with nonalcoholic fatty liver diseases].
    Xu L; Zhong Y; Su ST; Liu YG; Lyu FN; Zhou XL; Ren JQ; Li P; Shi RF; Jiang Y; Fan JG; Mi YQ
    Zhonghua Gan Zang Bing Za Zhi; 2020 Mar; 28(3):247-253. PubMed ID: 32306658
    [No Abstract]   [Full Text] [Related]  

  • 4. [A serum lipidomic study of patients with non-alcoholic fatty liver disease].
    Yang RX; Hu CX; Mi YQ; Sun WL; Chen GY; Pan Q; Shen F; Xu GW; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):122-127. PubMed ID: 28297799
    [No Abstract]   [Full Text] [Related]  

  • 5. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model.
    Hu D; Wang H; Wang H; Wang Y; Wan X; Yan W; Luo X; Ning Q
    Hepatol Int; 2018 Sep; 12(5):438-446. PubMed ID: 29974410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Quantitative detection and clinical value of CD44 in patients with nonalcoholic fatty liver disease].
    Fang M; Yao M; Yang JL; Wang L; Sun JY; Wu MN; Yao DF; Tai BJ
    Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):994-1000. PubMed ID: 31941262
    [No Abstract]   [Full Text] [Related]  

  • 7. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.
    Huang Y; Gan Q; Lai R; Wang W; Guo S; Sheng Z; Chen L; Guo Q; Cai W; Wang H; Zhao G; Cao Z; Xie Q
    Front Cell Infect Microbiol; 2021; 11():733348. PubMed ID: 35111690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    Ooi GJ; Meikle PJ; Huynh K; Earnest A; Roberts SK; Kemp W; Parker BL; Brown W; Burton P; Watt MJ
    J Hepatol; 2021 Sep; 75(3):524-535. PubMed ID: 33887358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing hepatic steatosis distribution patterns between non-alcoholic fatty liver disease and fatty liver disease with chronic hepatitis B by second-harmonic generation/two-photon excited fluorescence method.
    Zhuang Z; Qu H; Yang W; Liu J; Wang F; Liu Y; Ding J; Shi J
    Ann Hepatol; 2020; 19(3):313-319. PubMed ID: 31870745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An unbiased lipidomics approach identifies key lipid molecules as potential therapeutic targets of Dohongsamul-tang against non-alcoholic fatty liver diseases in a mouse model of obesity.
    Park SH; Lee JE; Lee SM; Lee J; Seo CS; Hwang GS; Jung J
    J Ethnopharmacol; 2020 Oct; 260():112999. PubMed ID: 32454173
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Xu QY; Li H; Cao HX; Pan Q; Fan JG
    Biomed Res Int; 2020; 2020():8869674. PubMed ID: 33294458
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Luo JJ; Cao HX; Yang RX; Zhang RN; Pan Q
    World J Clin Cases; 2018 Sep; 6(10):355-364. PubMed ID: 30283798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver Fatty Acid-binding Protein Is a More Reliable Biomarker for Liver Injury in Nonalcoholic Steatohepatitis than Other Etiologies of Hepatitis.
    Şen İ; Dumlu Ş
    Turk J Gastroenterol; 2024 Jul; 35(7):568-576. PubMed ID: 39128054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver Lipidomics Analysis Revealed the Protective mechanism of Zuogui Jiangtang Qinggan Formula in type 2 diabetes mellitus with non-alcoholic fatty liver disease.
    Zhou M; Liu X; Wu Y; Xiang Q; Yu R
    J Ethnopharmacol; 2024 Jul; 329():118160. PubMed ID: 38588985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Abnormal expression of CD44 aggravates liver disease progression in patients with non-alcoholic fatty liver disease accompanied with hepatitis B virus replication].
    Wu XF; Sha CX; Yang JL; Liu Y; Zhou P; Yao DF; Yao M
    Zhonghua Gan Zang Bing Za Zhi; 2021 Nov; 29(11):1083-1088. PubMed ID: 34933427
    [No Abstract]   [Full Text] [Related]  

  • 17. Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV-HIV Co-infected Adults.
    Sterling RK; King WC; Khalili M; Kleiner DE; Hinerman AS; Sulkowski M; Chung RT; Jain MK; Lisker-Melman MA; Wong DK; Ghany MG;
    Dig Dis Sci; 2022 Feb; 67(2):676-688. PubMed ID: 33559089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Monounsaturated Triacylglycerol Predicts Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease and Chronic Hepatitis B.
    Yang RX; Hu CX; Sun WL; Pan Q; Shen F; Yang Z; Su Q; Xu GW; Fan JG
    Sci Rep; 2017 Sep; 7(1):10517. PubMed ID: 28874844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL).
    Mocciaro G; Allison M; Jenkins B; Azzu V; Huang-Doran I; Herrera-Marcos LV; Hall Z; Murgia A; Susan D; Frontini M; Vidal-Puig A; Koulman A; Griffin JL; Vacca M
    Mol Metab; 2023 Jul; 73():101728. PubMed ID: 37084865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipidomic Analysis of the Protective Effects of Shenling Baizhu San on Non-Alcoholic Fatty Liver Disease in Rats.
    Deng Y; Pan M; Nie H; Zheng C; Tang K; Zhang Y; Yang Q
    Molecules; 2019 Oct; 24(21):. PubMed ID: 31683679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.